Pharmacokinetics and pharmacodynamics of gs-9350: A novel pharmacokinetic enhancer without Anti-HIV activity

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 3, 2010, Pages 322-329

  Mathias, A A ^a   German, P ^a   Murray, B P ^a   Wei, L ^a   Jain, A ^a   West, S ^a   Warren, D ^a   Hui, J ^a   Kearney, B P ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; ELVITEGRAVIR; GS 9350; MIDAZOLAM; PLACEBO; RITONAVIR; UNCLASSIFIED DRUG;

ABNORMAL DREAMING; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOMNOLENCE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HUMANS; ISOENZYMES; MALE; MIDAZOLAM; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; YOUNG ADULT;

EID: 77149123315     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.228     Document Type: Article

References (30)

1. Peck, R.W. Driving earlier Clinical attrition: if you want to fnd the needle, burn down the haystack. considerations for biomarker development. Drug Discov. Today 12, 289-294 (2007).
2. Kola, I. & Landis, J. can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).
3. Youle, M. Overview of boosted protease inhibitors in treatment- experienced hIV-infected patients. J. Antimicrob. Chemother. 60, 1195-1205 (2007).
4. Sension, M. & Piliero, P.J. Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients. J. Assoc. Nurses AIDS Care 18, 36-47 (2007).
5. Dunn, D. et al.; UK collaborative Group on hIV Drug Resistance. Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. Antivir. Ther. (Lond.) 13, 771-777 (2008).
6. Gallant, J.E. Protease-inhibitor boosting in the treatment-experienced patient. AIDS Rev. 6, 226-233 (2004).
7. Department of health and human Services (DhhS). Guidelines for the Use of antiretroviral agents in hIV-1-Infected adults and adolescents, 3 November 2008.
8. Shulman, N. et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob. Agents Chemother. 46, 3907-3916 (2002)
9. Katlama, C. et al. Efficacy of TMc114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-fnding trials. 12th conference on Retroviruses and Opportunistic Infections, Boston, Ma, 22-25 February 2005. abstract 164LB.
10. Malan, N. et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive hIV-1 infected subjects, both with and without ritonavir: 48-week results from aI424-089. 13th conference on Retroviruses and Opportunistic Infections, Denver, cO, 5-9 February 2006. abstract 107LB.
11. Hsu, A., Granneman, G.R. & Bertz, R.J. Ritonavir. Clinical pharmacokinetics and interactions with other anti-hIV agents. Clin. Pharmacokinet. 35, 275-291 (1998).
12. Wyen, C. et al. Efect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic cYP3a, cYP2D6 and P-glycoprotein in hIV-infected patients. Clin. Pharmacol. Ther. 84, 75-82 (2008).
13. Yeh, R.F. et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes cYP2c9, cYP2c19, and cYP1a2 but inhibits the hepatic and intestinal activity of cYP3a as measured by a phenotyping drug cocktail in healthy volunteers. J. Acquir. Immune Deffic. Syndr. 42, 52-60 (2006).
14. Hogeland, G.W., Swindells, S., McNabb, J.C., Kashuba, A.D., Yee, G.C. & Lindley, C.M. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin. Pharmacol. Ther. 81, 69-75 (2007).
15. Burger, D.M. et al. The efect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe. Clin. Pharmacol. Ther. 84, 698-703 (2008).
16. Foisy, M.M., Yakiwchuk, E.M. & hughes, C.A. Induction efects of ritonavir: implications for drug interactions. Ann. Pharmacother. 42, 1048-1059 (2008).
17. Zastre, J.a. et al. Up-regulation of P-glycoprotein by hIV protease inhibitors in a human brain microvessel endothelial cell line. J. Neurosci. Res. 87, 1023-1036 (2009).
18. Kharasch, E.D., Mitchell, D., Coles, R. & Blanco, R. Rapid Clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob. Agents Chemother. 52, 1663-1669 (2008).
19. Mathias, a.a., West, S., hui, J. & Kearney, B.P. Dose-response of ritonavir on hepatic cYP3a activity and elvitegravir oral exposure. Clin. Pharmacol. Ther. 85, 64-70 (2009).
20. Kappelhof, B.S. et al. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in hIV-1-infected patients. Br. J. Clin. Pharmacol. 59, 174-182 (2005).
21. Kappelhof, B.S. et al. Population pharmacokinetics of indinavir alone and in combination with ritonavir in hIV-1-infected patients. Br. J. Clin. Pharmacol. 60, 276-286 (2005).
22. Moltó, J. et al. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in hIV-infected adults. Clin. Pharmacokinet. 47, 681-692 (2008).
23. Dickinson, L. et al. Population pharmacokinetics of ritonavir-boosted saquinavir regimens in hIV-infected individuals. J. Antimicrob. Chemother. 62, 1344-1355 (2008).
24. Tsunoda, S.M., Velez, R.L., von Moltke, L.L. & Greenblatt, D.J. Diferentiation of intestinal and hepatic cytochrome P450 3a activity with use of midazolam as an in vivo probe: efect of ketoconazole. Clin. Pharmacol. Ther. 66, 461-471 (1999).
25. Kharasch, E.D., Walker, a., hofer, c. & Shefels, P. Intravenous and oral alfentanil as in vivo probes for hepatic and frst-pass cytochrome P450 3a activity: noninvasive assessment by use of pupillary miosis. Clin. Pharmacol. Ther. 76, 452-466 (2004).
26. Chen, M., Nafziger, A.N. & Bertino, J.S. Jr. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of cYP3a activity as measured by oral midazolam. Drug Metab. Dispos. 34, 2079-2082 (2006).
27. Thummel, K.E. et al. Oral frst-pass elimination of midazolam involves both gastrointestinal and hepatic cYP3a-mediated metabolism. Clin. Pharmacol. Ther. 59, 491-502 (1996).
28. US Department of health and human Services, Food and Drug administration, center for Drug Evaluation and Research (cDER), and center for Biologics Evaluation and Research (cBER). Drug Interaction Studies-Study Design, Data analysis, and Implications for Dosing and Labeling (Rockville, MD, 2006).
29. Gorski, J.C., Hall, S.D., Jones, D.R., VandenBranden, M. & Wrighton, S.A. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3a (cYP3a) subfamily. Biochem. Pharmacol. 47, 1643-1653 (1994).
30. Regulatory compliance center. Division of aIDS (DaIDS) table of grading severity of adult adverse experiences (National Institute of allergy and Infectious Diseases, Bethesda, MD, 1992).